RGD Reference Report - Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis.

Authors: Roca-Ferrer, J  Pujols, L  Gartner, S  Moreno, A  Pumarola, F  Mullol, J  Cobos, N  Picado, C 
Citation: Roca-Ferrer J, etal., Thorax. 2006 Jul;61(7):592-6. Epub 2006 Mar 3.
RGD ID: 5143924
Pubmed: PMID:16517580   (View Abstract at PubMed)
PMCID: PMC2104672   (View Article at PubMed Central)
DOI: DOI:10.1136/thx.2004.039842   (Journal Full-text)

BACKGROUND: Since abnormalities in prostanoid metabolism occur in the lower airway of patients with cystic fibrosis (CF), it is likely that they could also be detected in the nose. METHODS: The degree of mRNA and protein expression of cyclo-oxygenase (COX) enzymes 1 (COX-1) and 2 (COX-2) was examined using quantitative reverse competitive polymerase chain reaction (RT-PCR) and Western blot analysis in the nasal polyps from 10 patients with CF, nasal polyps from 10 non-CF patients and 11 nasal mucosa specimens. The results are presented as 10(6) cDNA molecules/mug total RNA and the densitometric ratio between protein and beta-actin. RESULTS: COX-1 mRNA levels were significantly higher in CF nasal polyps (median 2.34, 25-75th percentiles 1.6-3.2) than in the nasal mucosa (0.78, 0.11-1.21), while there was no difference with non-CF nasal polyps (1.11, 0.80-3.15). COX-1 protein levels were significantly higher in CF nasal polyps (3.63, 2.71-4.27) than in nasal mucosa (1.55, 0.66-2.33) and non-CF nasal polyps (2.19, 1.72-3.68). COX-2 mRNA was significantly higher in CF nasal polyps (3.34, 2.42-7.05) than in nasal mucosa (1.69, 0.19-3.50). No differences were found in COX-2 mRNA expression between CF and non-CF polyps (1.38, 0.12-6.07). COX-2 protein levels were also significantly higher in CF nasal polyps (0.23, 0.04-0.34) than in non-CF nasal polyps (0.011, 0.009-0.016) or nasal mucosa (0.014, 0.014-0.016). CONCLUSIONS: Upregulation in the expression of COX-1 and COX-2 could explain the high production of prostanoids reported in CF. These findings raise questions regarding the potential use of selective or non-selective COX-2 non-steroidal anti-inflammatory treatment in CF.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Nasal Polyps  IEP 5143924; 5143924associated with Cystic Fibrosis and protein:increased expression:nasal mucosa:RGD 
Nasal Polyps  ISOPTGS1 (Homo sapiens)5143924; 5143924associated with Cystic Fibrosis and protein:increased expression:nasal mucosa:RGD 
Nasal Polyps  ISOPTGS2 (Homo sapiens)5143924; 5143924associated with Cystic Fibrosis and protein:increased expression:nasal mucosa:RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ptgs1  (prostaglandin-endoperoxide synthase 1)
Ptgs2  (prostaglandin-endoperoxide synthase 2)

Genes (Mus musculus)
Ptgs1  (prostaglandin-endoperoxide synthase 1)
Ptgs2  (prostaglandin-endoperoxide synthase 2)

Genes (Homo sapiens)
PTGS1  (prostaglandin-endoperoxide synthase 1)
PTGS2  (prostaglandin-endoperoxide synthase 2)


Additional Information